186 related articles for article (PubMed ID: 27430524)
1. Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment.
Jog M; Wein T; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
Can J Neurol Sci; 2016 Sep; 43(5):687-96. PubMed ID: 27430524
[TBL] [Abstract][Full Text] [Related]
2. Long-term Safety and Dosing of OnabotulinumtoxinA: A Prospective, Observational Study.
Wein T; Jog M; Bhogal M; Dhani S; Miller R; Ismail F; Beauchamp R; Trentin G
Can J Neurol Sci; 2019 Nov; 46(6):742-752. PubMed ID: 31256770
[TBL] [Abstract][Full Text] [Related]
3. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
Hubble J; Schwab J; Hubert C; Abbott CC
Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
[TBL] [Abstract][Full Text] [Related]
4. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).
Jankovic J; Adler CH; Charles D; Comella C; Stacy M; Schwartz M; Manack Adams A; Brin MF
J Neurol Sci; 2015 Feb; 349(1-2):84-93. PubMed ID: 25595221
[TBL] [Abstract][Full Text] [Related]
5. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
Davies B; Gaul C; Martelletti P; García-Moncó JC; Brown S
J Headache Pain; 2017 Sep; 18(1):93. PubMed ID: 28879545
[TBL] [Abstract][Full Text] [Related]
6. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
7. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
[TBL] [Abstract][Full Text] [Related]
8. Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: A retrospective safety and efficacy evaluation.
Dursun N; Akarsu M; Gokbel T; Akyuz M; Karacan C; Dursun E
J Rehabil Med; 2019 May; 51(5):390-394. PubMed ID: 30931483
[TBL] [Abstract][Full Text] [Related]
9. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
Kongsengdao S; Kritalukkul S
J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
[TBL] [Abstract][Full Text] [Related]
11. Routine use of Xeomin in patients previously treated with Botox: long term results.
Dressler D
Eur J Neurol; 2009 Dec; 16 Suppl 2():2-5. PubMed ID: 20002739
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder.
Ginsberg DA; Drake MJ; Kaufmann A; Radomski S; Gousse AE; Chermansky CJ; Magyar A; Nicandro JP; Nitti VW;
J Urol; 2017 Oct; 198(4):897-904. PubMed ID: 28536084
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.
Kollewe K; Escher CM; Wulff DU; Fathi D; Paracka L; Mohammadi B; Karst M; Dressler D
J Neural Transm (Vienna); 2016 May; 123(5):533-40. PubMed ID: 27032774
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
Danchenko N; Johnston KM; Whalen J
J Med Econ; 2022; 25(1):919-929. PubMed ID: 35730362
[TBL] [Abstract][Full Text] [Related]
16. [Botulinum toxin therapy for focal dystonia].
Hahn K; Niklai E; Garzuly F; Szupera Z
Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
[TBL] [Abstract][Full Text] [Related]
17. Comparison of onabotulinumtoxinA and rimabotulinumtoxinB for the treatment of axillary hyperhidrosis.
An JS; Hyun Won C; Si Han J; Park HS; Seo KK
Dermatol Surg; 2015 Aug; 41(8):960-7. PubMed ID: 26218729
[TBL] [Abstract][Full Text] [Related]
18. Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II.
Kent R; Robertson A; Quiñones Aguilar S; Tzoulis C; Maltman J
Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357959
[TBL] [Abstract][Full Text] [Related]
19. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
[TBL] [Abstract][Full Text] [Related]
20. Subjective and Objective Measures in the Treatment of Hemifacial Spasm With OnabotulinumtoxinA.
Chundury RV; D'Angelo AS; Couch SM; Holds JB
Ophthalmic Plast Reconstr Surg; 2016; 32(2):133-7. PubMed ID: 25811161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
